Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Pinton, Giulia ^a   Manente, Arcangela Gabriella ^a   Angeli, Giovanni ^b   Mutti, Luciano ^b   Moro, Laura ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b Vercelli Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; PEMETREXED; PERIFOSINE; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; AKT1 PROTEIN, HUMAN; AKT3 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; EGFR PROTEIN, HUMAN; MET PROTEIN, HUMAN; PHOSPHORYLCHOLINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL MEMBRANE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MESOTHELIUM CELL; PHARMACOLOGICAL BLOCKING; PLEURA MESOTHELIOMA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; DRUG EFFECT; ENZYMOLOGY; MESOTHELIOMA; METABOLISM; PHOSPHORYLATION; PLEURA TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CISPLATIN; HUMANS; MESOTHELIOMA; PHOSPHORYLATION; PHOSPHORYLCHOLINE; PLEURAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84860993721     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036856     Document Type: Article

References (35)

1. Robinson BW, Lake RA, (2005) Advances in malignant mesothelioma. N Engl J Med 353: 1591-1603.
2. Kazan-Allen L, (2005) Asbestos and mesothelioma: worldwide trends. Lung Cancer 49: S3-8.
3. Campbell NP, Kindler HL, (2011) Update on malignant pleural mesothelioma. Semin Respir Crit Care Med 32: 102-10 Review.
4. Ray M, Kindler HL, (2009) Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 136(3) 888-96 Review.
5. Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, et al. (2007) Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 25: 2406-2413.
6. Mitsudomi T, Yatabe Y, (2007) Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98: 1817-1824.
7. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF, (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925.
8. Tolnay E, Kuhnen C, Wiethege T, König JE, Voss B, et al. (1998) Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased micro vessel density in malignant pleural mesothelioma. J Cancer Res Clin Oncol 124: 291-296.
9. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, et al. (2006) Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 66: 352-361.
10. Mukohara T, Civiello G, Davis IJ, Taffaro ML, Christensen J, et al. (2005) Inhibition of the met receptor in mesothelioma. Clin Cancer Res 11: 8122-8130.
11. Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, et al. (2009) Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis 30: 1097-1105.
12. Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, et al. (2005) Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 24: 6080-6089.
13. Carbone M, Yang H, (2012) Molecular Pathways: Targeting Mechanisms of Asbestos and Erionite Carcinogenesis in Mesothelioma. Clin Cancer Res. 18 (3): 598-604.
14. Cacciotti P, Barbone D, Porta C, Altomare DA, Testa JR, et al. (2005) SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res 65: 5256-5262.
15. Toker A, Cantley LC, (1997) Signaling through the lipid products of phosphoinositide-3-OH kinase. Nature 387: 673-676.
16. Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, et al. (1997) Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 277 567-570.
17. Bellacosa A, Chan TO, Ahmed NN, Datta K, Malstrom S, et al. (1998) Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 17: 313-325.
18. Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, et al. (1997) Role of translocation in the activation and function of protein kinase B. J Biol Chem 272: 31515-31524.
19. Vlahos CJ, Matter WF, Hui KY, Brown RF, (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269: 5241-8.
20. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF, (2008) The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 8: 187-98.
21. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK, (2003) Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 11: 1093-103.
22. Bendell JC, Nemunaitis J, Vukelja SJ, Hagenstad C, Campos LT, et al. (2011) Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. J Clin Oncol. 29 (33): 4394-400.
23. Richardson PG, Wolf J, Jakubowiak A, Zonder J, Lonial S, et al. (2011) Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol. 29 (32): 4243-9.
24. Hers I, Vincent EE, Tavaré JM, (2011) Akt signalling in health and disease. 10 Cell Signal pp. 1515-27.
25. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK, (2003) Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2: 1093-103.
26. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, et al. (2006) Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107: 4053-62.
27. Festuccia C, Gravina GL, Muzi P, Millimaggi D, Dolo V, et al. (2008) Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors. The Prostate 68: 965-974.
28. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, et al. (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318: 287-290.
29. Li X, Luwor R, Lu Y, Liang K, Fan Z, (2006) Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells. Oncogene. 25 (4): 525-35.
30. Cacciotti P, Libener R, Betta P, Martini F, Porta C, et al. (2001) SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. Proc Natl Acad Sci U S A 98: 12032-37.
31. Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, et al. (2000) Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol 20: 1436-47.
32. Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, et al. (2009) Oestrogen receptor β impacts on prognosis of human malignant mesothelioma. Cancer Res 69: 4598-604.
33. Brognard J, Clark AS, Ni Y, Dennis PA, (2001) Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61 (10): 3986-97.
34. Tallarida RJ, (2006) An Overview of Drug Combination Analysis with Isobolograms. J Pharmacol Exp Ther 19: 1-7.
35. Tallarida RJ, (2001) Drug synergism: its detection and applications. J Pharmacol Exp Ther 298: 865-72 Review.